Glucagon-like peptide-1 (GLP-1) agonists have been used to treat type 2 diabetes for over 20 years, but in recent years, they’ve gained significant attention for their potential weight loss benefits. Two medications, semaglutide and tirzepatide, are gaining popularity due to their high effectiveness.
What do these medications do? GLP-1 is a hormone produced by the small intestine that regulates blood sugar levels by triggering insulin release and suppressing glucagon production. GLP-1 agonists mimic this natural hormone, binding to receptors in the body and helping to manage blood sugar levels. They also slow down digestion and increase feelings of fullness after eating.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are two GLP-1 medications that have received FDA approval for diabetes treatment. While both medications are effective, tirzepatide has shown to be more effective for weight loss due to its dual action as a GLP-1 agonist and glucose-dependent insulinotropic polypeptide hormone receptor activator.
However, these medications also come with potential side effects. Common side effects include gastrointestinal issues, such as constipation and diarrhea, as well as cosmetic changes like hair loss and skin sagging. More severe side effects can include gallstones, pancreatitis, gastroparesis, kidney damage, and a potential risk of thyroid cancer.
It’s essential to consult with a healthcare provider before taking GLP-1 medications, as they may not be suitable for everyone. While these medications can be a powerful tool for improving health, it’s crucial to weigh the benefits against the risks and discuss personal goals and medical history with a trusted healthcare provider.
Source: https://uknow.uky.edu/uk-healthcare/new-generation-weight-loss-drugs-pros-and-cons-glp-1s